natgillin/translations-raw huggingface dataset:
a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted, 
4-člana do 6-člana heterociklička skupina koja sadrži od 0 do 1 kisikov atom i od 1 do 3 dušikova atoma kao heteroatoma, koja može biti supstituirana;
a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by one or more substituents selected from a halogen atom, a hydroxy group, an oxo group, a C1-10 alkoxy-carbonyl group, a C1-10 alkoxy group which can be substituted, and a C1-10 alkyl group which can be substituted, or wherein 
4-člana do 6-člana heterociklička skupina koja sadrži od 0 do 1 kisikov atom i od 1 do 3 dušikova atoma kao heteroatoma, koja može biti supstituirana s jednim ili više supstituenata odabranih od atoma halogena, hidroksi-skupine, okso-skupine, C1-10 alkoksi-karbonil-skupine, C1-10 alkoksi-skupine koja može biti supstituirana i C1-10 alkil-skupine koja može biti supstituirana.
one 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, a C1-10 alkoxy-carbonyl group, a C1-10 alkoxy group which can be substituted by halogen, and a C1-10 alkyl group which can be substituted by halogen, preferably wherein 
jedna 4-člana do 6-člana heterociklička skupina koja sadrži od 0 do 1 kisikov atom i od 1 do 3 dušikova atoma kao heteroatoma, koja može biti supstituirana s jednim do četiri supstituenta odabrana od atoma halogena, hidroksi-skupine, okso-skupine, C1-10 alkoksi-karbonil-skupine, C1-10 alkoksi-skupine koja može biti supstituirana s halogenom i C1-10 alkil-skupine koja može biti supstituirana s halogenom.
a tetrahydropyranyl group which can be substituted, 
tetrahidropiranil-skupina koja može biti supstituirana;
a C1-10 alkoxy group which can be substituted, 
C1-10 alkil-skupina koja može biti supstituirana;
a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by one or more substituents selected from a halogen atom, a hydroxy group, an oxo group, a C1-10 alkoxy-carbonyl group, a C1-10 alkoxy group which can be substituted, and a C1-10 alkyl group which can be substituted. 
4-člana do 6-člana heterociklička skupina koja sadrži od 0 do 1 kisikov atom i od 1 do 3 dušikova atoma kao heteroatoma, koja može biti supstituirana s jednim ili više supstituenata odabranih od atoma halogena, hidroksi-skupine, okso-skupine, C1-10 alkoksi-karbonil-skupine, C1-10 alkoksi-skupine koja može biti supstituirana i C1-10 alkil-skupine koja može biti supstituirana. Spoj prema zahtjevu 2, naznačen time, da
a 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, a C1-10 alkoxy-carbonyl group, a C1-10 alkoxy group which can be substituted by halogen, and a C1-10 alkyl group which can be substituted by halogen. 
4-člana do 6-člana heterociklička skupina koja sadrži od 0 do 1 kisikov atom, i od 1 do 3 dušikova atoma kao heteroatoma, koja može biti supstituirana s jednim do četiri supstituenta odabrana od atoma halogena, hidroksi-skupine, okso-skupine, C1-10 alkoksi-karbonil-skupine, C1-10 alkoksi-skupine koja može biti supstituirana s halogenom i C1-10 alkil-skupine koja može biti supstituirana s halogenom.
one 4- to 6-membered heterocyclic group containing 0 or 1 oxygen atom, and 1 to 3 nitrogen atoms as heteroatoms which can be substituted by 1 to 4 substituents selected from a halogen atom, a hydroxy group, an oxo group, a C1-10 alkoxy-carbonyl group, a C1-10 alkoxy group which can be substituted by halogen, and a C1-10 alkyl group which can be substituted by halogen, 
jedna 4-člana do 6-člana heterociklička skupina koja sadrži od 0 do 1 kisikov atom i od 1 do 3 dušikova atoma kao heteroatoma, koja može biti supstituirana s jednim do četiri supstituenta odabrana od atoma halogena, hidroksi-skupine, okso-skupine, C1-10 alkoksi-karbonil-skupine, C1-10 alkoksi-skupine koja može biti supstituirana s halogenom i C1-10 alkil-skupine koja može biti supstituirana s halogenom; Prsten B predstavlja pirazol-prsten.
a C3-7 cycloalkyl group which can be substituted, and 
C3-7 cikloalkil-skupina koja može biti supstituirana; i
a C3-7 cycloalkyl group which can be substituted, 
C3-7 cikloalkil-skupina koja može biti supstituirana;
a C1-10 alkyl group which can be substituted, 
C1-10 alkil-skupina koja može biti supstituirana;
a C1-10 alkoxy group which can be substituted, 
C1-10 alkoksi-skupina koja može biti supstituirana;
A compound of formula (I0): wherein 
Uporaba spoja formule (I0):
or a salt thereof, in the manufacture of a medicament for preventing or treating schizophrenia, Huntington's disease, bipolar disorder, neurodegeneration associated with stroke, neurodegeneration associated with cerebral infarct, autism, Alzheimer's disease, Parkinson's disease, obesity, drug addiction or attention deficit/hyperactivity disorder. 
ili njegova sol, naznačen time, da se upotrebljava u prevenciji ili liječenju shizofrenije, autizma, Alzheimerove bolesti, bipolarnog poremećaja, Parkinsonove bolesti, Huntingtonove bolesti, pretilosti, ovisnosti o drogama ili poremećaja pomanjkanja pažnje i hiperaktivnosti.
A combination for use according to claim 1 or 2, wherein said oligonucleotide comprises RNA. 
Kombinacija za uporabu u skladu s patentnim zahtjevom 1 ili 2, pri čemu navedeni oligonukleotid sadrži RNA.
A combination for use according to claim 3, wherein said RNA contains a 2'- O -methyl modified ribose (RNA). 
Kombinacija za uporabu u skladu s patentnim zahtjevom 3, pri čemu navedena RNA sadrži 2’-O-metil modificiranu ribozu (RNA).
a pharmaceutically acceptable carrier, adjuvant, diluent and/or excipient. 
farmaceutski prihvatljivi nosač, adjuvans, diluent i/ili ekscipijens.
is chosen from the series consisting of (C3-C7)-cycloalkyl, R32-CuH2u- and Het3-CuH2u-, wherein u is an integer chosen from the series consisting of 0, 1, 2 and 3; 
je odabran iz niza koji čine (C3-C7)-cikloalkil, i R32-CuH2u-, pri čemu u je cijeli broj odabran iz niza koji čine 0, 1, 2 i 3;
A process for the preparation of a compound of the formula I or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them as claimed in any one or more of claims 1 to 5, comprising reacting a compound of the formula II with a compound of the formula III, wherein the groups Ht, G, R10, R11, R30, R40, R50 and R60 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group J in the compound of the formula II is HO-, (C1-C4)-alkyl-O- or halogen. 
Postupak za pripremanje spoja s formulom I ili neke njegove fiziološki prihvatljive soli, ili fiziološki prihvatljivog solvata bilo kojeg od njih prema bilo kojem ili više zahtjeva 1 do 6, naznačen time da sadrži reakciju spoja s formulom II sa spojem s formulom III, [image] pri čemu skupine Ht, G, R10, R11, R30, R40, R50 i R60 u spojevima s formulama II i III su definirane kao u spojevima s formulom I, a dodane funkcionalne skupine mogu biti prisutne u zaštićenom obliku ili u obliku prekursorske skupine, i skupina J u spoju s formulom II je HO-, (C1-C4)-alkil-O- ili halogen.
A compound of the formula I as claimed in any one or more of claims 1 to 5 or a physiologically acceptable salt thereof or a physiologically acceptable solvate of any of them for the treatment of heart failure, congestive heart failure, cardiomyopathy, myocardial infarction, left ventricular dysfunction, cardiac hypertrophy, valvular heart diseases, hypertension, atherosclerosis, peripheral arterial occlusive disease, restenosis, vasvular permeability disorders, treatment of edema, thrombosis, rheumatoid arthritis, osteoarthritis, renal failure, cystic fibrosis, chronic bronchitis, chronic obstructive pulmonary disease, asthma, immunological diseases, diabetic complications, fibrotic diseases, pain, ischemia or reperfusion damage or neurodegenerative diseases, or for cardioprotection or renoprotection or as a diuretic (stand-alone treatment or in combination with established diuretics). 
Uporaba spoja s formulom I prema bilo kojem ili više zahtjeva 1 do 6 ili njegova fiziološki prihvatljiva sol, ili fiziološki prihvatljiv solvat bilo kojeg od njih naznačena time da je za proizvodnju lijeka za liječenje zatajenja srca, kongestivnog zatajenja srca, kardiomiopatija, infarkta miokarda, lijeve ventrikularne disfunkcije, srčane hipertrofije, bolesti srčanih zalistaka, hipertenzije, ateroskleroze, bolesti začepljenja perifernih arterija, restenoza, poremećaja propusnosti zalistaka, liječenja edema, tromboze, reumatoidnog artritisa, osteoartritisa, zatajenja bubrega, cistične fibroze, kroničnog bronhitisa, kronične opstruktivne plućne bolesti, astme, imunoloških bolesti, dijabetičkih komplikacija, fibroznih bolesti, boli, ishemijske ili reperfuzijske ozljede ili neurodegenerativnih bolesti, ili za zaštitu srca ili zaštitu bubrega ili kao diuretik (samostalni tretman ili tretman u kombinaciji s utvrđenim diureticima).
A method for controlling a pest, which comprises applying an effective amount of the anthranilamide compound or its salt as defined in Claim 1. 
Postupak za nadzor štetočina, naznačen time, da se sastoji od primjene učinkovite količine antranilamidnog spoja ili njegove soli kao što je definirano u patentnom zahtjevu 1, osim kao postupak za liječenje ljudskog ili životinjskog tijela terapijom.
wherein the 5-membered ring formed by A1, A2, U, T, and V is aromatic; 
pri čemu je 5-člani prsten koji formira atom ugljika, atom dušika, U, T, i V aromatski;
or Rc and Rd together with the N atom to which they are attached form a 4-, 5-, 6- or 7-membered heterocycloalkyl group optionally substituted with 1, 2, or 3 substituents independently selected from Cy1, -(C1-6 alkyl)-Cy1 OH, CN, amino, halo, C1-6 alkyl, C1-6 haloalkyl, C1-6 haloalkyl, and halosulfanyl; 
ili Rc i Rd zajedno sa atomom dušika na koji su spojeni formiraju 4-, 5-, 6- ili 7-članu heterocikloalkilnu grupu opcionalno supstituiranu sa 1, 2, ili 3 supstituenta nezavisno odabrana od OH, CN, amino, halo, C1-6 alkila, C1-6 haloalkila, arila, arilalkila, heteroarila, heteroarilalkila, cikloalkila i heterocikloalkila;
A process for the preparation of a compound of formula (I): wherein R1 is C1-C6 alkyl or benzyl; 
Postupak za pripremu spoja formule (I): [image] gdje R1 je C1-C6 alkil ili benzil;
reacting a compound of formula (II): wherein R1 is as defined for formula (I); 
reakciju spoja formule (II): [image] gdje R1 je kao što je definirano za formulu (I);
with 2-quinoline carboxaldehyde under acidic conditions and at a temperature of ≤ 10°C; 
sa 2-hinolin karboksaldehidom pod kiselim uvjetima i na temperaturi od ≤ 10°C;
to give an acid addition salt of a compound of formula (III): wherein R1 is as defined for formula (I); 
da se dobije kisela adicijska sol spoja formule (III): [image] gdje R1 je kao što je definirano za formulu (I);
when the reaction of step (i) is substantially complete, treating the acid addition salt with a base to obtain the alcohol of formula (III), while maintaining the temperature at ≤ 10°C; and 
kada je reakcija koraka (i) završena u značajnoj mjeri, tretiranje kisele adicijske soli sa bazom se dobije alkohol formule (III), uz održavanje temperature na ≤ 10°C; i
reacting the compound of formula (III) with a reducing agent to give a compound of formula (I). 
reakciju spoja formule (III) sa reducirajućim agensom da se dobije spoj formule (I).
A process according to claim 1 or claim 2, wherein the reaction of step (i) is carried out in dichloromethane; and/or wherein the acid conditions in step (i) are provided by trifluoroacetic acid (TFA). 
Postupak prema patentnom zahtjevu 1 ili patentnom zahtjevu 2, gdje je reakcija koraka (i) izvedena u diklorometanu; i/ili gdje su kiseli uvjeti u koraku (i) osigurani sa trifluoro octenom kiselinom (TFA).
A process according to claim 3 wherein the TFA is present in an amount of ≥ 2 moles of acid per mole of compound of formula (II). 
Postupak prema patentnom zahtjevu 3 gdje je TFA prisutan u količini od ≥ 2 mola kiseline po molu spoja formule (II).
converting the compound of formula (I) to (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid, the process comprising hydrolysing the compound of formula (I). 
konvertiranja spoja formule (I) do (5-fluoro-2-metil-3-hinolin-2-ilmetil-indol-1-il)-octene kiseline, pri čemu postupak sadrži hidrolizu spoja formule (I).
A process according to any one of the preceding claims, further comprising before step (i), preparing a compound of formula (II) by a process comprising: 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, koji dodatno sadrži prije koraka (i), pripremu spoja formule (II) pomoću postupka koji sadrži:
reacting 5-fluoro-2-methyl indole with a compound of the formula (IV): 
reakciju 5-fluoro-2-metil indola sa spojem formule (IV):
X-CH2-COOR1 (IV) where X is a leaving group, for example a halo group such as bromo and R1 is as defined for formula (I). 
X-CH2-COOR1 (IV) gdje je X odlazeća grupa, na primjer halo grupa kao što je bromo i R1 je kao što je definirana za formulu (I).
A process according to claim 13 wherein the reaction takes place in the presence of caesium carbonate in acetonitrile; and/or wherein the amount of solvent is about 10 volumes of solvent per gram of 5-fluoro-2-methyl indole; and/or wherein the process further comprises isolating and purifying the compound of formula (II) before step (i). 
Postupak prema patentnom zahtjevu 13 gdje se reakcija odvija u prisustvu cezijeva karbonata u acetonitrilu; i/ili gdje je količina otapala oko 10 volumena otapala po gramu 5-fluoro-2-metil indola; i/ili gdje postupak dodatno sadrži izolaciju i pročišćavanje spoja formule (II) prije koraka (i).
An isolated and purified compound of formula (III): wherein R1 is C1-C6 alkyl or benzyl. 
Izolirani i prečišćeni spoj formule (III): [image] gdje R1 je C1-C6 alkil ili benzil.
R7, R8 are independently selected from H, F, Cl, Br; 
, R8 su neovisno odabrani od H, F, Cl, Br;
A compound of formula I and/or a pharmaceutically acceptable salt thereof according to any one of claims 1 to 5 for use in the treatment or prevention of sleep-related respiratory disorders, central and obstructive sleep apneas, upper airway resistance syndrome, Cheyne-Stokes respiration, snoring, disrupted central respiratory drive, sudden child death, postoperative hypoxia and apnea, muscle-related respiratory disorders, respiratory disorders after long-term mechanical ventilation (weaning), respiratory disorders during adaptation in high mountains, acute and for respiratory disorders, chronic lung disorders with hypoxia and hypercapnia, chronic obstructive pulmonary disease (COPD) and obesity hypoventilation syndrome. 
Spoj s formulom I i/ili njegova farmaceutski prihvatljiva sol prema bilo kojem od zahtjeva 1 do 5 naznačen time da je za uporabu za liječenje ili sprječavanje respiratornih poremećaja povezanih sa spavanjem, središnjih i opstrukcijskih apneja za vrijeme spavanja, sindroma povećanog otpora gornjih dišnih putova, Cheyne-Stokesovog disanja, hrkanja, poremećenog središnjeg respiratornog nagona, iznenadne dječje smrti, postoperativne hipoksije i apneje za vrijeme spavanja, respiratornih poremećaja povezanih s mišićima, respiratornih poremećaja nakon dugotrajne mehaničke ventilacije (odvikavanje), respiratornih poremećaja kod prilagodbe u visokim planinama, akutnih respiratornih poremećaja, kroničnih plućnih bolesti s hipoksijom i hiperkapnijom, kronične opstruktivne plućne bolesti (KOPB) i sindroma pretilosti–hipoventilacije.
The compound of claim 8, or a pharmaceutically acceptable salt, or solvate thereof, for the use of claim 8 wherein the cancer is brain, lung, squamous cell, bladder, gastric, pancreatic, breast, head, neck, renal, kidney, ovarian, prostate, colorectal, oesophageal, testicular, gynecological or thyroid cancer, melanoma, myelogenous leukemia, multiple myeloma, chronic myelogneous leukemia or myeloid cell leukemia. 
Spoj prema zahtjevu 8, ili njegova farmaceutski prihvatljiva sol ili solvat, za uporabu prema zahtjevu 8 naznačen time da rak je rak mozga, pluća, skvamoznih stanica, mjehura, rak želuca, gušterače, dojke, glave, vrata, bubrega, jajnika, prostate, rak debelog crijeva, jednjaka, rak testisa, ginekološki rak ili rak štitnjače, melanom, mijelogena leukemija, multipli mijelom, kronična mijelogena leukemija ili leukemija mijeloidnih stanica.
Set (kit) consisting of separate packs of an effective amount of a compound according to one or more of Claims 1 to 3 or a pharmaceutically acceptable salt or solvate thereof, and an effective amount of a further medicament active ingredient. 
Komplet (kit) naznačen time da sadrži odvojena pakiranja učinkovite količine spoja prema jednom ili više zahtjeva 1 do 3 ili njegove farmaceutski prihvatljive soli ili solvata, te učinkovite količine spoja dodatnog lijeka u vidu aktivnog sastojka.
The compound according to claim 1, wherein said compound is selected from the group of 
Spoj prema zahtjevu 1, naznačen time da se navedeni spoj odabire iz skupine koju čine
A pharmaceutically or veterinarily acceptable formulation adapted to be injected into an animal, which formulation comprises; 
Farmaceutska ili veterinarski prihvatljiva formulacija, naznačena time, da je prilagođena za ubrizgavanje u životinju, pri čemu ta formulacija obuhvaća sljedeće:
an effective amount of at least one macrocyclic lactone; 
učinkovitu količinu najmanje jednog makrocikličkog laktona;
a pharmaceutically acceptable system of solvents and surfactants wherein the system provides for acceptable storage stability for both the levamisole and the macrocyclic lactone and wherein the system provides for a viscosity which is suitable for injection; 
farmaceutski prihvatljiv sustav otapala i tenzida, dok taj sustav doprinosi prihvatljivoj stabilnosti kod skladištenja oba sredstva – levamisola i makrocikličkog laktona, te pritom sustav doprinosi viskozitetu koji je prikladan za injekciju;
wherein the system comprises at least one surfactant, wherein the surfactant is CREMOPHOR EL, and a water miscible organic solvent which is dimethylacetamide (DMA). 
pri čemu sustav sadrži najmanje jedan tenzid, dok tenzid je CREMOPHOR EL, i organsko otapalo koje se može miješati s vodom, a to je dimetilacetamid (DMA).
The formulation of claim 1 wherein the levamisole is levamisole phosphate and wherein the levamisole is present in an amount sufficient to deliver a dose of at least 4 mg/kg animal bodyweight. 
Formulacija prema zahtjevu 1, naznačena time, da levamisol je levamisol-fosfat i pritom je levamisol prisutan u količini dovoljnoj za pripravu doze od najmanje 4 mg/kg prema masi životinje.
The formulation of claim 1, wherein the macrocyclic lactone is either ivermectin or eprinomectin and is present in an amount sufficient to deliver a dose of at least 150 µg/kg animal bodyweight. 
Formulacija prema zahtjevu 1, naznačena time, da makrociklički lakton je bilo ivermektin ili eprinomektin, i prisutan je u količini dovoljnoj za pripravu doze od najmanje 150 μg/kg prema masi životinje.
The formulation of claim 5 wherein the macrocyclic lactone is eprinomectin and its concentration is about 0.5% to about 0.9% (w/v); the levamisole is levamisole phosphate and its concentration is about 18% to about 25% (w/v); the surfactant is CREMOPHOR EL, or a combination of CREMOPHOR EL and POLYSORBATE 80, and its concentration is about 3% to about 7% (w/v); the antioxidant is BHT; the solvent is DMA and its concentration is about 1% to about 10% (w/v); and the preservative is methyl paraben. 
Formulacija prema zahtjevu 5, naznačena time, da makrociklički lakton je eprinomektin i njegova koncentracija je od oko 0,5% do oko 0,9% (masa/volumen); levamisol je levamisol-fosfat i njegova koncentracija je od oko 18% do oko 25% (masa/volumen); tenzid je CREMOPHOR EL ili je kombinacija od sredstava CREMOPHOR EL i POLYSORBAT 80, i njihova koncentracija je od oko 3% do oko 7% (masa/volumen); antioksidant je BHT; otapalo je DMA i njegova koncentracija je od oko 1% do oko 10% (masa/volumen); a konzervans je metilparaben.
A pharmaceutically or veterinarily acceptable formulation adapted to be injected into an animal, which formulation comprises; 
Farmaceutska ili veterinarski prihvatljiva formulacija koja je prilagođena za ubrizgavanje u životinju, naznačena time, da formulacija obuhvaća sljedeće:
a pharmaceutically acceptable system of solvents and surfactants wherein the system provides for acceptable storage stability for both the levamisole and the macrocyclic lactone and wherein the system provides for a viscosity which is suitable for injection; 
farmaceutski prihvatljiv sustav otapala i tenzida, dok taj sustav doprinosi prihvatljivoj stabilnosti kod skladištenja za oba sredstva – levamisol i makrociklički lakton, te pritom sustav doprinosi viskozitetu koji je prikladan za injekciju;
in a separate vessel dissolving Eprinomectin and BHT in DMA, 
otapanje eprinomektina i BHT u DMA u odvojenoj posudi;
A concentrated solution comprising two triazole compounds and a water-miscible solvent where the two triazole compounds are selected from cyproconazole, propiconazole and difenoconazole; the total concentration of the two triazole compounds is from 0.5 to 600g/l; and the ratio of the total weight of the two triazole compounds to the total weight of any water-immiscible solvent is greater than 2 to 1. 
Koncentrirana otopina koja sadrži dva spoja triazola i otapalo koje se miješa s vodom gdje su dva spoja triazola odabrana od ciprokonazola, propikonazola i difenokonazola; te je ukupna koncentracija dvaju spojeva triazola od 0.5 do 600 g/l; i omjer ukupne težine dvaju spojeva triazola prema ukupnoj težini bilo kojeg otapala koje se ne miješa s vodom je veći od 2 prema 1.
A solution according to claim 2 in which the total concentration of the two triazole compounds is from 200 to 450g/l. 
Otopina prema zahtjevu 2, naznačena time da je ukupna koncentracija dvaju spojeva triazola od 200 do 450 g/l.
A solution according to claim 4 in which the water-miscible solvent is tetrahydrofurfuryl alcohol. 
Otopina prema zahtjevu 4, naznačena time da otapalo koje se miješa s vodom je tetrahidrofurfuril alkohol.
The compound of claim 1, wherein (a) R1', R2', R3' and R4' are hydrogen; (b) R1' and R4' are hydrogen; and one of R2' and R3' is hydrogen, and the other is selected from halo, methyl optionally substituted with one or more halo, or -O-methyl optionally substituted with one or more halo; (c) R1' and R2', or R2' and R3', or R3' and R4', taken together with carbon atoms to which they are attached, form a 5- or 6-membered carbocycle or heterocycle (e.g., phenyl), and the rest of R1', R2', R3' and R4' are hydrogen. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da su (a) R1, R2, R3 i R4 vodik; da su (b) R1 i R4 vodik; ijedan od R2 i R3 je vodik, a drugi je odabran od halo, metila po izboru supstituiranog s jednim ili više halo ili -O- metila po izboru supstituiranog s jednim ili više halo; (c) R1 i R2 ili R2 i R3 ili R3 a R4, zajedno s ugljikovim atomima za kojeg su vezani tvore 5-ero ili 6-eročlani karbocikl ili heterocikl (npr., fenil), a ostatak R1, R2, R3 i R4 su vodik.
The composition of claim 20, wherein said additional anti-hepatitis C virus agent is selected from the group consisting of a-interferon, β-interferon, ribavarin, and adamantine. 
Pripravak u skladu s patentnim zahtjevom 20, naznačen time, da rečeno dodatno sredstvo protiv virusa hepatitisa C je odabrano iz skupine koja se sastoji od a-interferona, β-interferona, ribavarina i adamantina.